FDA Approves Supplemental Application for Farxiga (Dapagliflozin)
The FDA has approved a supplemental application for Farxiga, an SGLT2 inhibitor developed by AstraZeneca.
Published: July 23, 2026
Updated: July 23, 2026
Author: Humanexa Intelligence
Therapeutic area: Diabetes / SGLT2 Inhibitor
Company: AstraZeneca
Asset: Farxiga
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Company
AstraZeneca
Asset
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's approval of the supplemental application for Farxiga is significant as it strengthens AstraZeneca's position in the competitive diabetes market. This could lead to increased market share and influence future treatment guidelines.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor for any upcoming data releases or marketing strategies following this approval.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.